μαθιψΰφθν θας ® 250 ξ"β

φεψϊ ξϊο

PER OS

ξιπεο

Tablets

ωιξεω αϊψετδ

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

ξρτψ ψιωεν

141 43 31958 00

ιφψο

Teva Pharmaceutical Industries Ltd

ϊεχσ ψιωιεο μϊψετδ

08/2014 - 08/2024

• δηξψδ μςμεο μφψλο
• ςμεο μφψλο

δερτϊ ϊβεαδ ηγωδ ων * λεϊψϊ * ςζεψ μπε μεεγΰ ωΰϊδ μΰ ψεαεθ δϊβεαδ ωμκ χιωεψιν ιδτλε αΰετο ΰεθεξθι μμηιφιν   αωμιηϊ ϊβεαδ ΰπι ξχαμ ΰϊ ϊπΰι δωιξεω αΰϊψ.